ATE445164T1 - Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie - Google Patents

Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie

Info

Publication number
ATE445164T1
ATE445164T1 AT00401778T AT00401778T ATE445164T1 AT E445164 T1 ATE445164 T1 AT E445164T1 AT 00401778 T AT00401778 T AT 00401778T AT 00401778 T AT00401778 T AT 00401778T AT E445164 T1 ATE445164 T1 AT E445164T1
Authority
AT
Austria
Prior art keywords
compositions
methods
treating
tumor cells
detecting
Prior art date
Application number
AT00401778T
Other languages
English (en)
Inventor
Michel Vidaud
Ivan Bieche
Original Assignee
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Descartes filed Critical Univ Paris Descartes
Application granted granted Critical
Publication of ATE445164T1 publication Critical patent/ATE445164T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT00401778T 2000-06-22 2000-06-22 Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie ATE445164T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00401778A EP1167975B1 (de) 2000-06-22 2000-06-22 Zusammensetzungen und Methoden zum Nachweis, Behandeln oder Vorhersagen der Antwort von Brust Tumorzellen auf eine Endocrin-Therapie

Publications (1)

Publication Number Publication Date
ATE445164T1 true ATE445164T1 (de) 2009-10-15

Family

ID=8173738

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00401778T ATE445164T1 (de) 2000-06-22 2000-06-22 Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie

Country Status (3)

Country Link
EP (1) EP1167975B1 (de)
AT (1) ATE445164T1 (de)
DE (1) DE60043100D1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437962T1 (de) * 2002-10-01 2009-08-15 Epigenomics Ag Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
EP3470535B1 (de) 2003-06-24 2020-04-01 Genomic Health, Inc. Vorhersage der wahrscheinlichkeit eines wiederauftretens von krebs
WO2008133493A1 (en) * 2007-04-27 2008-11-06 Erasmus University Medical Center Rotterdam Prediction of responsiveness to anti-estrogen treatment in breast cancer
US20170010267A1 (en) * 2012-10-17 2017-01-12 Runlin Z MA Shon as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy
CN114045336B (zh) * 2021-09-28 2024-01-02 中国人民解放军空军军医大学 Cga基因作为靶点在制备用于诊断和治疗耐药实体瘤药物的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608143D0 (en) * 1996-04-19 1996-06-26 Ver Nl Kanker Inst Assay
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin

Also Published As

Publication number Publication date
EP1167975A1 (de) 2002-01-02
DE60043100D1 (de) 2009-11-19
EP1167975B1 (de) 2009-10-07

Similar Documents

Publication Publication Date Title
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
IL149922A (en) Tweak receptor antagonist for use in regulating the angiogenesis process, a nucleic acid encoded by the antagonist, expression and host cells that contain the expression carrier and the antagonist to produce the antagonist
DE60134178D1 (de) Trp8 krebsmarker
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
DK0917571T3 (da) Hidtil ukendt agoutirelateret gen
BR0209646A (pt) genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos
FI113377B (fi) Yhdistelmäviruspartikkelin valmistusmenetelmä käytettäväksi syöpäsolun kasvainilmiasun estossa
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
ATE445164T1 (de) Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie
BRPI0418229A (pt) genes do ciclo celular e métodos corrrelatos de uso
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
ATE557092T1 (de) Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
DE69943129D1 (de) Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
MXPA05006034A (es) Proteina de duplicacion.
WO2002064023A3 (en) Fra-1 expression in brain cancer
TW200501988A (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
DE69619683T2 (de) Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
DE69734143D1 (de) Neue methoden zur charakterisierung von verbindungen, welche die stf-1 expression in inselzellen der bauchspeicheldrüse stimuliert
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
ATE466958T1 (de) Klassifizierung von kolonkrebs
DE60230684D1 (de) Sak: modulation der zellproliferation zur krebsbehandlung
WO2003106648A3 (en) COMPOSITIONS AND METHODS RELATED TO BREAST SPECIFIC GENES AND PROTEINS
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
DE69738433D1 (de) Rezeptor-tyrosine-kinase gene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1167975

Country of ref document: EP